Orchid Pharma Limited

BSE: 524372 NSE: ORCHPHARMA
Orchid Pharma Limited - pharma in Chengalpattu, Tamil Nadu, India. FY 2026 financials & compliance.
CIN L24222TN1992PLC022994 Incorporated 01 July 1992 ROC Chennai HQ Chengalpattu, Tamil Nadu, India
Active Listed - NSE: ORCHPHARMA · BSE: 524372 Public Limited Company pharma
Data last updated
Market Cap
₹4,930 Cr
ORCHPHARMA · NSE
Share Price
₹818.35
-0.60% today
Revenue
₹1,233 Cr
FY 2025-26 · +33.7% YoY
EBITDA
₹26.24 Cr
Margin 2.1%
Net Profit
₹17.29 Cr
FY 2025-26 · -82.7% YoY
P/E (TTM)
273.0x
P/B 3.2x
Authorised capital
₹150 Cr
Registered with MCA
Paid-up capital
₹50.72 Cr
Issued & subscribed

About Orchid Pharma Limited

Data last updated:

Orchid Pharma Limited is a public limited company based in Chengalpattu, Tamil Nadu, India, a subsidiary of Dhanuka Laboratories Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 July 1992 and has been in existence for over 34 years.

The company is registered with the Registrar of Companies (ROC), Chennai, under CIN L24222TN1992PLC022994. Its GSTIN is 33AAACO0402B1ZJ (Tamil Nadu). The company holds 12 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524372 and NSE: ORCHPHARMA.

The company has an authorised share capital of ₹150 Cr and a paid-up capital of ₹50.72 Cr. It was formerly known as Orchid Chemicals & Pharmaceuticals Limited. It is led by directors including Manish Dhanuka (Managing Director) and Mridul Dhanuka (Whole-Time Director).

Its last annual general meeting (AGM) was held on 20 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No 121 – 128 128A – 133 138 – 151 159 – 164, SIDCO Industrial Estate Alathur Chengalpattu, Tamil Nadu, India – 603110.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,232.78 Cr, a growth of 33.7% compared to the previous year. For the same year it recorded a net profit of ₹17.29 Cr (net margin 1.4%) and EBITDA of ₹26.24 Cr (EBITDA margin 2.1%). The net worth stands at ₹1,564.31 Cr (up 0.7% YoY). Total assets are valued at ₹1,884.31 Cr (up 10% YoY).

The company has about 1,101 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Orchid Pharma. As per MCA filings, the company has open charges of ₹366.5 Cr and satisfied charges of ₹15,354 Cr on record. Court records list 412 cases involving the company, including 181 filed by the company and 231 filed against it; 63 cases are pending. The company has 80 deals on record (72 market trades, 4 funding rounds, 2 acquisitions), with disclosed funding of ₹184.55 Cr; the latest was in May 2025. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Win-Medicare Private Limited with revenue of ₹1,012.12 Cr. The company has 24 MSME Form 1 returns on record between 2003 and 2024, listing 1,215 overdue payments to 131 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website orchidpharma.com.

Company details

CIN L24222TN1992PLC022994
Registration Number 022994
Incorporation Date 01 July 1992
ROC Chennai
Listing Status Listed - Listed on NSE (ORCHPHARMA); Listed on BSE (524372)
Company Status Active
Date of Last AGM 20 September 2025
Date of Balance Sheet 31 March 2026
Parent Company Dhanuka Laboratories Limited
Compliance Status Active Compliant

CIN history

Orchid Pharma has one previous CIN (Corporate Identification Number): U24222TN1992PLC022994. The current CIN is L24222TN1992PLC022994, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24222TN1992PLC022994Current
U24222TN1992PLC022994Previous
Key People
Manish Dhanuka Managing Director Mridul Dhanuka Whole-Time Director Ram Gopal Agarwal Director

Contact details

Orchid Pharma Limited's registered office is in Chengalpattu, Tamil Nadu. Its website is orchidpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    orchidpharma.com
  • Registered Address
    Plot No 121 – 128 128A – 133 138 – 151 159 – 164, SIDCO Industrial Estate Alathur Chengalpattu, Tamil Nadu, India – 603110
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Orchid Pharma Limited, buy the company report.

Comprehensive company report
Orchid Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Orchid Pharma operates one associated brand: Orchid Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Orchid Pharma
Bulk actives, formulations, and nutraceuticals are developed and manufactured.orchidpharma.com

Business activity

The main business activity of Orchid Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Orchid Pharma Limited, buy the company report.

Financials of Orchid Pharma Limited

FY 2025-26 filings available

Orchid Pharma Limited reported revenue of ₹1,232.78 Cr (up 33.7% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,233 Cr
+33.7% YoY
EBITDA
₹26.24 Cr
-77.7% YoY
Profit After Tax
₹17.29 Cr
-82.7% YoY
Net Worth
₹1,564 Cr
+0.7% YoY
Total Assets
₹1,884 Cr
+10.0% YoY
Total Debt
₹307 Cr
+99.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,233922819666560450484
Revenue growth+33.7%+12.5%+23.1%+19.0%+24.3%-7.0%-
EBITDA26.2411811177.5254.5829.37(31.18)
EBITDA margin+2.1%+12.8%+13.6%+11.6%+9.8%+6.5%-6.4%
Profit before tax10.4395.5791.9548.471.57(117)(131)
Net profit17.2999.9892.366.32(2.46)(118)(131)
Net profit margin+1.4%+10.8%+11.3%+1.0%-0.4%-26.3%-27.1%
EPS (₹)1.6619.6518.1711.35(0.48)(28.55)(32.11)
Balance sheet
Total assets1,8841,7121,3081,0339261,1171,344
Net worth1,5641,5541,169689647653766
Total debt307154135331268453566
Cash & bank83.5220126730.638.0619.91174
Net working capital555733545312217418457
Cash flow
Cash from operations12651.3712618.3492.4723.5980.80
Cash from investing(277)(36.48)(312)(31.21)11367.21167
Cash from financing1372.4616731.17(217)(165)(250)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue304368207194263237217223
Revenue growth (YoY)+15.6%+55.1%-4.6%-13.1%+7.7%---
Other income1.837.775.6110.7711.573.908.497.52
EBITDA14.0029.94(5.55)(1.48)(5.64)27.9826.3630.34
EBITDA margin+4.6%+8.1%-2.7%-0.8%-2.1%+11.8%+12.1%+13.6%
Depreciation10.9510.909.038.9010.538.878.618.63
Interest2.231.963.183.732.283.923.803.33
Profit before tax2.6524.85(12.15)(3.34)(6.88)19.0922.4425.90
Tax0.070.000.000.000.00(0.04)0.000.00
Net profit2.5824.85(12.15)(3.34)(6.88)19.1322.4425.90
EPS (₹)0.544.31(2.49)(1.13)(0.95)4.404.105.37
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,233922819666557451481
Revenue growth+33.7%+12.5%+23.1%+19.6%+23.6%-6.3%-
EBITDA30.4512411183.2458.7037.50(49.98)
EBITDA margin+2.5%+13.4%+13.6%+12.5%+10.5%+8.3%-10.4%
Profit before tax34.6210691.5354.19(4.81)(117)(150)
Net profit41.9510794.9514.19(5.32)(118)(150)
Net profit margin+3.4%+11.6%+11.6%+2.1%-1.0%-26.2%-31.2%
EPS (₹)5.7820.9918.6813.28(1.18)(28.70)(36.71)
Balance sheet
Total assets1,7911,7691,3571,0769571,1461,376
Net worth1,6471,6111,218732678681798
Total debt129154135331268453566
Cash & bank66.5118525722.344.2118.97172
Net working capital575760587350249452494
Cash flow
Cash from operations14263.5413113.3989.5724.3680.42
Cash from investing(116)(50.80)(316)(26.70)11367.21167
Cash from financing(40.74)2.6816731.17(217)(165)(250)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue304368207194263237217223
Revenue growth (YoY)+15.6%+55.1%-4.6%-13.1%+7.7%---
Other income10.0513.7310.5915.4316.056.269.947.96
Total expenses289336212194269203191193
EBITDA15.0032.07(4.27)(0.67)(5.63)34.3326.3629.59
EBITDA margin+4.9%+8.7%-2.1%-0.3%-2.1%+14.5%+12.1%+13.3%
Depreciation10.9011.188.978.7910.538.768.618.63
Interest2.211.953.173.732.283.983.793.30
Profit before tax11.9432.67(5.82)2.24(2.39)27.8523.9025.62
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue304368207194263237217223
Revenue growth (YoY)+15.6%+55.1%-4.6%-13.1%+7.7%---
Other income1.837.775.6110.7711.573.908.497.52
EBITDA14.0029.94(5.55)(1.48)(5.64)27.9826.3630.34
EBITDA margin+4.6%+8.1%-2.7%-0.8%-2.1%+11.8%+12.1%+13.6%
Depreciation10.9510.909.038.9010.538.878.618.63
Interest2.231.963.183.732.283.923.803.33
Profit before tax2.6524.85(12.15)(3.34)(6.88)19.0922.4425.90
Tax0.070.000.000.000.00(0.04)0.000.00
Net profit2.5824.85(12.15)(3.34)(6.88)19.1322.4425.90
EPS (₹)0.544.31(2.49)(1.13)(0.95)4.404.105.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,233922819666560450484
Revenue growth+33.7%+12.5%+23.1%+19.0%+24.3%-7.0%-
Other income36.4227.4730.8658.6467.4715.2124.28
Total expenses1,207804708588505421515
Employee cost0.0086.3669.6465.3563.2867.1174.86
EBITDA26.2411811177.5254.5829.37(31.18)
EBITDA margin+2.1%+12.8%+13.6%+11.6%+9.8%+6.5%-6.4%
Depreciation43.2534.5533.2454.7987.02109118
Interest8.9814.9316.7432.9033.4652.216.23
Profit before tax10.4395.5791.9548.471.57(117)(131)
Tax(0.19)(0.19)(3.12)0.000.000.000.00
Net profit17.2999.9892.366.32(2.46)(118)(131)
Net profit margin+1.4%+10.8%+11.3%+1.0%-0.4%-26.3%-27.1%
EPS (₹)1.6619.6518.1711.35(0.48)(28.55)(32.11)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital59.8959.8950.7240.8240.8240.8240.82
Reserves & surplus1,5041,4941,050579538544725
Shareholders' funds (net worth)1,5641,5541,169689647653766
Minority interest0.000.000.000.000.000.000.00
Secured loans28070.5114.27223208389492
Unsecured loans26.5883.2012110960.3863.5074.47
Total debt307154135331268453566
Total liabilities1,8841,7121,3081,0339261,1171,344
Assets
Gross block1,5171,4991,3011,2211,1761,1761,247
Net block692708620573584670858
Capital work in progress41480.7130.6746.469.787.4325.61
Investments66.9759.9045.8244.4445.4915.430.34
Inventories372457264229173153142
Sundry debtors38135319621517113667.97
Cash & bank balances83.5220126730.638.0619.91174
Loans & advances92.0886.4864.4226.4546.37226186
Total current assets9291,098791501398535569
Total current liabilities374365246189181117113
Net working capital555733545312217418457
Total assets1,8841,7121,3081,0339261,1171,344
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash21.183.8322.604.3115.6989.8992.31
Net cash from operating activities12651.3712618.3492.4723.5980.80
Net cash from investing activities(277)(36.48)(312)(31.21)11367.21167
Net cash from financing activities1372.4616731.17(217)(165)(250)
Net change in cash(14.10)17.34(19.00)18.29(11.39)(74.20)(2.42)
Closing cash83.5220126730.638.0619.91174
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+33.7%+12.5%+23.1%+19.0%+24.3%-7.0%-
EBITDA growth-77.7%+5.9%+43.3%+42.0%+85.8%+194.2%-
PBT growth-89.1%+3.9%+89.7%+2987.3%+9998.0%+11.1%-
Net income growth-82.7%+8.3%+1361.4%+356.9%+97.9%+9.7%-
Revenue CAGR (3Y)+22.8%+18.1%+22.1%+11.2%-2.3%-13.0%-15.3%
EBITDA CAGR (3Y)-30.3%+29.2%+55.8%--+6.5%-27.9%
Profitability & leverage
Net income margin+0.9%+10.4%+11.6%+7.3%+0.3%-25.9%-27.1%
Return on capital employed-+3.2%+3.2%+1.5%-1.1%0.0%0.0%
Return on net worth-+2.9%+3.0%+0.3%+0.1%0.0%0.0%
Debt / equity-0.130.250.450.550.7261.28
Long-term debt / equity-0.100.170.300.490.6631.13
Interest cover-52.7917.9821.51144.74-103.14-65.63-4.18
Efficiency & per share
Fixed asset turnover-0.700.650.560.480.370.35
Inventory turnover-3.123.323.323.443.063.11
Debtors turnover-4.223.993.453.654.425.15
EPS (₹)1.6619.6518.1711.35(0.48)(28.55)(32.11)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00236.35217.06151.92141.81143.16187.67
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue304368207194263237217223
Revenue growth (YoY)+15.6%+55.1%-4.6%-13.1%+7.7%---
Other income10.0513.7310.5915.4316.056.269.947.96
Total expenses289336212194269203191193
EBITDA15.0032.07(4.27)(0.67)(5.63)34.3326.3629.59
EBITDA margin+4.9%+8.7%-2.1%-0.3%-2.1%+14.5%+12.1%+13.3%
Depreciation10.9011.188.978.7910.538.768.618.63
Interest2.211.953.173.732.283.983.793.30
Profit before tax11.9432.67(5.82)2.24(2.39)27.8523.9025.62
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,233922819666557451481
Revenue growth+33.7%+12.5%+23.1%+19.6%+23.6%-6.3%-
Other income56.4931.9330.3958.6456.976.4624.28
Total expenses1,202798708583498413531
Employee cost0.0086.3669.6465.3560.2164.4071.60
EBITDA30.4512411183.2458.7037.50(49.98)
EBITDA margin+2.5%+13.4%+13.6%+12.5%+10.5%+8.3%-10.4%
Depreciation43.3634.4433.2254.7987.02109118
Interest8.9614.9316.7132.9033.4652.216.22
Profit before tax34.6210691.5354.19(4.81)(117)(150)
Tax0.000.00(3.23)0.000.000.000.00
Net profit41.9510794.9514.19(5.32)(118)(150)
Net profit margin+3.4%+11.6%+11.6%+2.1%-1.0%-26.2%-31.2%
EPS (₹)5.7820.9918.6813.28(1.18)(28.70)(36.71)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital59.8959.8950.7240.8240.8240.8240.82
Reserves & surplus1,5871,5511,099623569572688
Shareholders' funds (net worth)1,6471,6111,218732678681798
Secured loans10270.5114.05223171367492
Unsecured loans26.5883.1612110997.3285.9074.47
Total debt129154135331268453566
Total liabilities1,7911,7691,3571,0769571,1461,376
Assets
Gross block1,4951,4791,2971,2201,1761,1761,247
Net block671688616573584670858
Capital work in progress16843.9224.4646.099.787.4325.61
Investments87.5979.5869.4050.1249.0115.430.34
Inventories372457264229173151141
Sundry debtors38135318921216013266.38
Cash & bank balances66.5118525722.344.2118.97172
Loans & advances61.2680.8471.4730.8145.99226185
Total current assets8811,077782494383527565
Total current liabilities30731719514413475.6270.76
Net working capital575760587350249452494
Total assets1,7911,7691,3571,0769571,1461,376
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash15.940.5318.310.4514.7588.1790.97
Net cash from operating activities14263.5413113.3989.5724.3680.42
Net cash from investing activities(116)(50.80)(316)(26.70)11367.21167
Net cash from financing activities(40.74)2.6816731.17(217)(165)(250)
Net change in cash(14.64)15.41(18.01)17.86(14.30)(73.42)(2.79)
Closing cash66.5118525722.344.2118.97172
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+33.7%+12.5%+23.1%+19.6%+23.6%-6.3%-
EBITDA growth-75.4%+11.6%+33.4%+41.8%+56.5%+175.0%-
PBT growth-67.5%+16.3%+68.9%+9998.0%+95.9%+21.8%-48.3%
Net income growth-60.7%+12.5%+569.1%+366.7%+95.5%+21.2%-
Revenue CAGR (3Y)+22.8%+18.3%+22.1%+11.4%-1.6%-11.2%-14.0%
EBITDA CAGR (3Y)-28.5%+28.3%+43.6%--+19.1%-11.0%
Profitability & leverage
Net income margin+2.8%+11.6%+11.6%+8.1%-0.9%-26.0%-31.1%
Return on capital employed-+3.6%+3.3%+2.3%0.0%0.0%0.0%
Return on net worth-+3.3%+3.2%+0.8%0.0%0.0%0.0%
Debt / equity-0.120.240.430.530.6988.62
Long-term debt / equity-0.100.140.250.470.6345.02
Interest cover-69.4016.6821.46115.64-118.15-73.12-3.70
Efficiency & per share
Fixed asset turnover-0.700.650.560.470.370.36
Inventory turnover-3.123.323.323.453.093.13
Debtors turnover-4.284.083.583.814.544.65
EPS (₹)5.7820.9918.6813.28(1.18)(28.70)(36.71)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00247.54226.69162.53149.30150.13178.67

To see the full year-wise statements and ratios of Orchid Pharma Limited, buy the company report.

Board of directors of Orchid Pharma Limited

Orchid Pharma has 8 current directors and 32 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ram Gopal Agarwal
Also directs: Orchid Bio-Pharma Limited, H D Realtors Private Limited
Director31 Mar 20206 Years 6 MonthsCurrent
Mridul Dhanuka
Also directs: Dhanuka Laboratories Limited, Orbion Pharmaceuticals Private Limited, Orchid Bio-Pharma Limited and 1 more
Whole-Time Director31 Mar 20206 Years 6 MonthsCurrent
Dharam VirDirector29 Jun 20206 Years 3 MonthsCurrent
Tanu SinglaDirector29 Jun 20206 Years 3 MonthsCurrent
Manoj Kumar Goyal
Also directs: People for Change Foundation
Director29 Jun 20206 Years 3 MonthsCurrent
Manish Dhanuka
Also directs: Dhanuka Laboratories Limited, Orchid Bio-Pharma Limited, Dhanuka Agritech Limited and 2 more
Managing Director31 Mar 20206 Years 6 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Orchid Pharma Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Orchid Pharma Limitedthis company₹1,232.78 Cr (FY 2026)₹17.29 Cr1.4%33.7%1,101Chengalpattu, Tamil Nadu, India
Win-Medicare Private Limited₹1,012.12 Cr (FY 2025)7.0%New Delhi, Delhi, India
Umedica Laboratories Private Limited₹993.72 Cr (FY 2025)21.0%Pardi, Gujarat, India
Franco-Indian Pharmaceuticals Private Limited₹988.53 Cr (FY 2024)0.0%Mumbai, Maharashtra, India
Meyer Organics Private Limited₹984.18 Cr (FY 2025)12.0%Thane, Maharashtra, India
Biocon Pharma Limited₹982.5 Cr (FY 2025)11.0%Bangalore, Karnataka, India
Fresenius Kabi India Private Limited₹934 Cr (FY 2025)10.0%Ranjangaon, Maharashtra, India
Lee Pharma Limited₹928.7 Cr (FY 2025)2.0%Hyderabad, Telangana, India
Punjab Chemicals and Crop Protection Limited₹901.95 Cr (FY 2025)-4.0%Derabassi, Punjab, India
Rubicon Research Limited₹872.39 Cr (FY 2024)108.0%Thane, Maharashtra, India

To see the full peer comparison of Orchid Pharma Limited, buy the company report.

Auditor

Orchid Pharma Limited is audited by Singhi & Co. for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Singhi & Co.FY 2024302049E

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 69.80%, foreign institutional investors hold 0.80%, domestic institutional investors hold 20.80% and retail and other public shareholders hold 8.60%.

Promoters: 69.80%DII (Domestic Institutional): 20.80%FII (Foreign Institutional): 0.80%Retail & Others: 8.60%
Sep 2026
QUARTER
69.80% Promoters
20.80% DII (Domestic Institutional)
0.80% FII (Foreign Institutional)
8.60% Retail & Others
Promoter holding - history
Now 69.80% · Sep 2026High 69.80% · Dec 2025Low 69.80% · Dec 2025
68%68.8%69.5%70.3%71%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 69.80%Mar 2026: 69.80%Jun 2026: 69.80%Sep 2026: 69.80%69.80%69.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters69.80%69.80%69.80%69.80%
Public30.20%30.20%30.20%30.20%

Charges & borrowings

Open charges
₹366.5 Cr
Satisfied charges
₹15,354 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹291.50 Cr
Yes Bank Limited₹75.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
17 Jul 2025101132171Hdfc Bank Limited₹142.5 CrOpen
27 Aug 2022100615515Yes Bank Limited₹75 CrOpen
15 Nov 2021100520456Hdfc Bank Limited₹149 CrOpen
02 Aug 2023100764993Hdfc Bank Limited₹50 CrSatisfied
06 Jul 2020100350828Others₹229.67 CrSatisfied

To see the full charge records of Orchid Pharma Limited, buy the company report.

Total charge records: 179 View all charges

Deals & funding

Orchid Pharma Limited has 80 deals on record (72 market trades, 4 funding rounds, 2 acquisitions), with disclosed funding of ₹184.55 Cr; the latest was in May 2025.

Total deals
80
Market trades
72
Funding rounds
4
Acquisitions
2
QIP
1
Disclosed funding
₹184.55 Cr

Deals on record (5 of 80)

WhenDealAmountParties
Nov 2023Market trade₹148.53 CrBuyer: Uti Mutual Fund
Seller: Dhanuka Laboratories Limited
Jun 2021Secondary share transferUndisclosedSeller: Dhanuka Laboratories Limited
Apr 2020AcquisitionUndisclosedBuyer: Dhanuka Laboratories Limited
Jan 2018Market trade₹1.91 CrSeller: Fortune Intercontinental Private Limited
Oct 2015Funding round₹18.43 CrInvestors: Orchid Health Care Private Limited

To see the full deal history of Orchid Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Orchid Pharma Limited was last rated by Care on 27 Dec 2021.

Rating agencyRated onRating
Care27 Dec 2021

To see the full credit ratings and regulatory alerts of Orchid Pharma Limited, buy the company report.

MSME payment delays

Orchid Pharma Limited has 24 MSME Form 1 returns on record between 2003 and 2024, listing 1,215 overdue payments to 131 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 131)

SupplierAmount dueDue sinceReported on
Arunodya Coal Traders Private Limited
an individual supplier
an individual supplier
Asia Crystal Commodity LLP
Biolabs and Life Sciences LLP

To see the full MSME payment records of Orchid Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Orchid Pharma has 1 subsidiary company and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
1
Associated companies
Key subsidiaries
Company NameCINShares held
Orchid Bio-Pharma LimitedU24230TN2022PLC150784

To see the full group structure of Orchid Pharma Limited, buy the company report.

Employees & EPFO

Orchid Pharma Limited has a workforce of 1,101 employees on its EPFO records as of Nov 28, 2025, across 1 active EPFO establishment.

Employee count
1,101
Active EPFO establishments
1
Employee growth
3.19%

GST

Orchid Pharma has 12 GST registrations: 4 active and 8 cancelled or inactive.

Total GSTINs
12
Active
4
Cancelled / inactive
8
GSTINStateStatusRegistered on
33AAACO0402B1ZJTamil NaduActive01 Jul 2017
33AAACO0402B2ZITamil NaduActive05 Aug 2017
06AAACO0402B1ZGHaryanaActive20 Sep 2022
08AAACO0402B2ZBRajasthanActive16 Oct 2025

To see the full GST registrations and return filing status of Orchid Pharma Limited, buy the company report.

Recent activity

Orchid Pharma Limited has 65 board changes on record since 1992: 37 appointments and 28 cessations. The latest: Shubha Singh was appointed as Director on 23 May 2024.

Filing
Orchid Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chennai.
Charges
A charge with Hdfc Bank Limited of Rs. 142.50 Cr registered on 17 Jul 2025 with Charge ID 101132171 was modified on 08 Oct 2025.
AGM
Orchid Pharma Limited last Annual general meeting of members was held on 20 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 142.50 Cr with Charge ID 101132171 was registered on 17 Jul 2025.
Appointed
Shubha Singh was appointed as Director.
Ceased
Mudit Tandon ceased to be Director.
Charges
A charge with Yes Bank Limited of Rs. 75.00 Cr registered on 27 Aug 2022 with Charge ID 100615515 was modified on 10 Jan 2024.
Charges
A charge with Hdfc Bank Limited of Rs. 149.00 Cr registered on 15 Nov 2021 with Charge ID 100520456 was modified on 10 Jan 2024.
Charges
A charge registered on 02 Aug 2023 via Charge ID 100764993 with Hdfc Bank Limited was fully satisfied on 29 Nov 2023.
Appointed
Arjun Dhanuka was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 50.00 Cr with Charge ID 100764993 was registered on 02 Aug 2023.
Charges
A charge registered on 06 Jul 2020 via Charge ID 100350828 with Others was fully satisfied on 20 Jul 2023.

513 earlier events are in the company report.

News

Orchid Pharma: Buys Land In Kancheepuram And Finalizes Lease Deal With DBS Bank.
23 Sep 2026 · Exchange Update

Frequently asked questions

Orchid Pharma is an active public limited company based in Chengalpattu, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 July 1992 (34+ years old) and is registered under CIN L24222TN1992PLC022994. Listed on BSE: 524372 and NSE: ORCHPHARMA.

Orchid Pharma reported revenue of ₹1,232.78 Cr for FY 2025-26 (up 33.7% YoY) based on consolidated financials.

Orchid Pharma has 8 current directors:

The latest financial statements of Orchid Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 20 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Orchid Pharma is 33AAACO0402B1ZJ, registered in Tamil Nadu. The company has 12 GST registrations in all, of which 4 are active and 8 are cancelled or inactive. Other active GSTINs include 33AAACO0402B2ZI (Tamil Nadu), 06AAACO0402B1ZG (Haryana), 08AAACO0402B2ZB (Rajasthan).

The CIN (Corporate Identification Number) of Orchid Pharma is L24222TN1992PLC022994. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Orchid Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 524372) and NSE (symbol: ORCHPHARMA).

Orchid Pharma has 412 court cases on record: 181 filed by the company and 231 filed against it. 63 are pending. Most are in the district courts.

Orchid Pharma was incorporated on 01 July 1992, making it 34+ years old. It is registered with the Registrar of Companies, Chennai.

Orchid Pharma has 80 deals on record (72 market trades, 4 funding rounds, 2 acquisitions), with disclosed funding of ₹184.55 Cr; the latest was in May 2025.

The peers of Orchid Pharma by revenue are Win-Medicare Private Limited, Umedica Laboratories Private Limited, Franco-Indian Pharmaceuticals Private Limited, Meyer Organics Private Limited, Biocon Pharma Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Shubha Singh was appointed as Director on 23 May 2024. Mudit Tandon ceased to be Director on 12 Apr 2024. Arjun Dhanuka was appointed as Director on 20 Oct 2023. Orchid Pharma has 65 board changes on record in total.